CO5271716A1 - CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED - Google Patents
CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACEDInfo
- Publication number
- CO5271716A1 CO5271716A1 CO00085285A CO00085285A CO5271716A1 CO 5271716 A1 CO5271716 A1 CO 5271716A1 CO 00085285 A CO00085285 A CO 00085285A CO 00085285 A CO00085285 A CO 00085285A CO 5271716 A1 CO5271716 A1 CO 5271716A1
- Authority
- CO
- Colombia
- Prior art keywords
- crystals
- carboxamine
- tetrahydroquinoline
- replaced
- imf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Se describen formas cristalinas de un inhibidor de CETP, procedimiento preparar los cristales, procedimientos de uso de los cristales y composiciones farmacéuticas que contienen los cristales.<EMI FILE="00085285_1" ID="1" IMF=JPEG >Crystalline forms of a CETP inhibitor, method of preparing the crystals, methods of using the crystals and pharmaceutical compositions containing the crystals are described. <EMI FILE = "00085285_1" ID = "1" IMF = JPEG>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5271716A1 true CO5271716A1 (en) | 2003-04-30 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00085285A CO5271716A1 (en) | 1999-11-30 | 2000-11-09 | CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (en) |
JP (1) | JP2003515592A (en) |
KR (1) | KR20020058057A (en) |
CN (1) | CN1402711A (en) |
AP (1) | AP2002002531A0 (en) |
AU (1) | AU1048801A (en) |
BG (1) | BG106854A (en) |
BR (1) | BR0015836A (en) |
CA (1) | CA2392979A1 (en) |
CO (1) | CO5271716A1 (en) |
EA (1) | EA200200510A1 (en) |
EC (1) | ECSP003792A (en) |
EE (1) | EE200200277A (en) |
GT (1) | GT200000199A (en) |
HU (1) | HUP0203521A2 (en) |
IL (1) | IL149097A0 (en) |
IS (1) | IS6338A (en) |
MA (1) | MA26845A1 (en) |
MX (1) | MXPA02005354A (en) |
NO (1) | NO20022558L (en) |
OA (1) | OA12099A (en) |
PA (1) | PA8506301A1 (en) |
PE (1) | PE20010904A1 (en) |
PL (1) | PL355892A1 (en) |
TN (1) | TNSN00231A1 (en) |
TR (1) | TR200201446T2 (en) |
UY (1) | UY26454A1 (en) |
WO (1) | WO2001040190A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
PL368850A1 (en) * | 2001-06-21 | 2005-04-04 | Pfizer Products Inc. | Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors |
GT200200170A (en) | 2001-09-28 | 2003-05-23 | PREPARATION OF INHIBITOR OF CETP ANHIDRO | |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
KR100664822B1 (en) * | 2002-02-01 | 2007-01-04 | 화이자 프로덕츠 인코포레이티드 | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
DE60320940D1 (en) | 2002-02-01 | 2008-06-26 | Pfizer Prod Inc | PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DISPERSIONS OF ACTIVE SUBSTANCES AND LIPOPHILIC MICROPHASE-BASED MATERIALS |
DE60311821T2 (en) | 2002-08-30 | 2007-10-31 | Japan Tobacco Inc. | DIBENZYLAMINE COMPOUND AND THEIR MEDICAL USE |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
CA2500582A1 (en) | 2002-10-04 | 2004-04-22 | Millennium Pharmaceuticals, Inc. | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
ATE461700T1 (en) | 2002-12-20 | 2010-04-15 | Pfizer Prod Inc | DOSAGE FORM CONTAINING A CETP INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR |
EA200501376A1 (en) * | 2003-03-28 | 2006-04-28 | Пфайзер Продактс Инк. | DERIVATIVES OF 1,2,4-SUBSTITUTED 1,2,3,4-TETRAHYDRO- and 1,2-DIHYDROCHINOLINES AND 1,2,3,4-TETRAHYDROCHINOXALINE AS AN INHIBITORS CETR FOR THE TREATMENT OF ATHEROSCLEROSIS AND FAT |
BRPI0413277A (en) | 2003-08-04 | 2006-10-10 | Pfizer Prod Inc | pharmaceutical compositions of amorphous drug adsorbates and lipophilic microphase forming materials |
KR20060085675A (en) | 2003-10-08 | 2006-07-27 | 일라이 릴리 앤드 캄파니 | Compounds and methods for treating dyslipidemia |
AU2005233160B2 (en) * | 2004-04-13 | 2011-06-02 | Merck Sharp & Dohme Corp. | CETP inhibitors |
AU2005267436A1 (en) * | 2004-06-24 | 2006-02-02 | Eli Lilly And Company | Compounds and methods for treating dyslipidemia |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
BRPI0608553A2 (en) | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | pgd2 receptor antagonists for the treatment of inflammatory diseases |
WO2006098394A1 (en) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | Method for inhibiting lipid absorption and lipid absorption inhibitor |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
TW200901959A (en) | 2007-03-09 | 2009-01-16 | Indigene Pharmaceuticals Inc | Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
EP2379562A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
TWI450896B (en) | 2009-06-30 | 2014-09-01 | Lilly Co Eli | Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid |
PT3174995T (en) | 2014-07-30 | 2020-10-15 | Hoffmann La Roche | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
AU5731098A (en) * | 1997-02-03 | 1998-08-25 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/en unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/en unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/en not_active IP Right Cessation
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/en unknown
- 2000-11-14 IL IL14909700A patent/IL149097A0/en unknown
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/en unknown
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/en not_active Application Discontinuation
- 2000-11-14 EA EA200200510A patent/EA200200510A1/en unknown
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/en unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/en active Pending
- 2000-11-14 PL PL00355892A patent/PL355892A1/en not_active Application Discontinuation
- 2000-11-14 EE EEP200200277A patent/EE200200277A/en unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/en active Pending
- 2000-11-28 UY UY26454A patent/UY26454A1/en not_active Application Discontinuation
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/en not_active Application Discontinuation
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/en unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/en unknown
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/en unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/en unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/en unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/en not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IS6338A (en) | 2002-04-12 |
PL355892A1 (en) | 2004-05-31 |
PE20010904A1 (en) | 2001-09-10 |
EA200200510A1 (en) | 2002-10-31 |
OA12099A (en) | 2006-05-04 |
CN1402711A (en) | 2003-03-12 |
JP2003515592A (en) | 2003-05-07 |
GT200000199A (en) | 2002-05-23 |
CA2392979A1 (en) | 2001-06-07 |
MA26845A1 (en) | 2004-12-20 |
WO2001040190A1 (en) | 2001-06-07 |
UY26454A1 (en) | 2001-07-31 |
HUP0203521A2 (en) | 2003-02-28 |
IL149097A0 (en) | 2002-11-10 |
MXPA02005354A (en) | 2002-12-11 |
TNSN00231A1 (en) | 2002-05-30 |
ECSP003792A (en) | 2002-04-23 |
AU1048801A (en) | 2001-06-12 |
NO20022558D0 (en) | 2002-05-29 |
TR200201446T2 (en) | 2002-11-21 |
PA8506301A1 (en) | 2002-08-26 |
NO20022558L (en) | 2002-05-29 |
EE200200277A (en) | 2003-10-15 |
KR20020058057A (en) | 2002-07-12 |
EP1246804A1 (en) | 2002-10-09 |
BR0015836A (en) | 2002-08-06 |
AP2002002531A0 (en) | 2002-06-30 |
BG106854A (en) | 2002-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5271716A1 (en) | CRYSTALS OF 4- CARBOXAMINE 1,2,3,4-TETRAHYDROQUINOLINE 2- REPLACED | |
KR100263496B1 (en) | Taxol derivatives and preparation method thereof | |
DK0914119T3 (en) | Process for the preparation of solid oral dosage forms of valsartan | |
EP0931788A3 (en) | Metalloprotease inhibitors | |
PT1193270E (en) | PYRROLOBENZODIAZEPINAS | |
CO5160257A1 (en) | N-PIPERIDINO-5- (4-BROMOFENIL) -1- (2,4-DICLOROPHENIL) -4-ETILPIRAZOL-3-CARBOXAMIDE, ITS SALTS, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | |
AR002156A1 (en) | USE OF LIVE ESPOSROSISTS OR EIMERIA OOCYST, OR A MIXTURE OF THE SAME | |
ATE236123T1 (en) | THERMODYNAMICALLY STABLE MODIFICATION OF 1-(4-CARBAZOLYLOXY)-3-(2-(2-METHOXYPHENOXY)ETHYLAMINO)-2-PROPANOL, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
DE69009746D1 (en) | DERIVATIVES OF N-PHENYLBENZAMIDE WITH ANTIULCERATIVE AND ANTIALLERGIC ACTIVITY AND METHOD FOR THE PRODUCTION THEREOF. | |
ATE171188T1 (en) | 4-AZASTEROIDS SUBSTITUTED IN THE 15 POSITION | |
TR199801513A2 (en) | N- (4-Trifluoromethylphenyl) - 5- methyl-isoxazole-4-carboxamide crystal form. | |
BR9914787A (en) | Process for the preparation of a compound | |
SE8904298D0 (en) | NEW COMPOUNDS | |
DK293088D0 (en) | DOPAMINE-BETA-HYDROXYLASE INHIBITORS | |
SE9902550D0 (en) | New crystalline forms | |
IT1293777B1 (en) | PROCESS FOR THE PREPARATION OF TETRAAZAMACROCYCLES | |
CO5280205A1 (en) | CRYSTAL FORM OF EPLERENONE. | |
YU79602A (en) | Sodium-hydrogen exchanger type 1 inhibitor (nhe-1) | |
DK0635490T3 (en) | Process for the preparation of N-ethylcarbazole | |
SE9402241L (en) | Inhibitor | |
CO5080790A1 (en) | ACRIDINE DERIVATIVES AND PROCEDURE FOR THE PREPARATION OF SUCH DERIVATIVES | |
CO5271714A1 (en) | INHIBITOR CRYSTALS OF THE SODIUM-HYDROGEN EXCHANGER | |
CO5180571A1 (en) | CRYSTALLINE FORM III OF THE N- (4-DIMETHYLAMINONAFTALEN-1 SULPHONYLAMINE) PHENYL) -3-HYDROXI-2,2-DIMETHYLPROPIONAMIDE | |
NO901422D0 (en) | PROCEDURE FOR THE PREPARATION OF ALFA-GLUCOSIDASE INHIBITORS. | |
PT1007498E (en) | METHOD FOR THE MANUFACTURE OF 2-HALOGENOINDANE-1-ONES |